Pre-made Marstacimab biosimilar ( Whole mAb, anti-ERBB2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-336
Anti-ERBB2 therapeutic antibody (Pre-made Marstacimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Developed by Pfizer, marstacimab is a laboratory-engineered monoclonal antibody designed to treat hemophilia A and B patients, with or without inhibitors. ... Investigators collected blood and plasma samples from 12 participants with either hemophilia A or B, regardless of the presence of inhibitor antibodies.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ERBB2 therapeutic antibody (Pre-made Marstacimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|